RxDoctor Payments Data

Thomas Carson, MD

Family Medicine · Tarpon Springs, FLNPI 1427058791

Payments from drug & device makers

$3,712in general payments, 2019–2025

Across 201 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$721
  • Lilly USA, LLC$385
  • Pfizer$358
  • Boehringer Ingelheim$319
  • Merck$220
  • Johnson & Johnson$216
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,69399%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,712 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$16,769
Medicare patients
127
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$52,775
OzempicSemaglutide36$43,215
JardianceEmpagliflozin28$34,002
XareltoRivaroxaban15$25,059
JanuviaSitagliptin Phosphate18$22,765
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,234
Repatha SyringeEvolocumab11$9,028
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,162
Levothyroxine Sodium203$2,005
Gabapentin96$1,811
Atorvastatin Calcium234$1,805
Omeprazole81$1,614
Duloxetine Hcl49$1,443
Metoprolol Succinate116$1,398
Mirtazapine27$1,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$358$52,77547 claims
Novo NordiskOzempic$145$43,21536 claims
Boehringer IngelheimJardiance$319$34,00228 claims
Johnson & JohnsonXarelto$216$25,05915 claims
MerckJanuvia$220$22,76518 claims
GSKTrelegy Ellipta$127$12,23413 claims
AbbVieSynthroid$137$94211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Tarpon Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →